Literature DB >> 25155796

Prostate cancer: Enzalutamide AFFIRMs its benefits.

Robert Phillips.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25155796     DOI： 10.1038/nrurol.2014.227

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

Authors:  Karim Fizazi; Howard I Scher; Kurt Miller; Ethan Basch; Cora N Sternberg; David Cella; David Forer; Mohammad Hirmand; Johann S de Bono
Journal:  Lancet Oncol       Date:  2014-08-04       Impact factor: 41.316

2.  Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.

Authors:  Klaus Brasso; Frederik B Thomsen; Andres J Schrader; Sebastian C Schmid; David Lorente; Margitta Retz; Axel S Merseburger; Christoph A von Klot; Martin Boegemann; Johann de Bono
Journal:  Eur Urol       Date:  2014-08-06       Impact factor: 20.096
  2 in total
  1 in total

1.  Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  ZhenHeng Wei; ChuXin Chen; BoWen Li; YongYue Li; Hong Gu
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.